Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive randomized home treatment trial for COVID-19 with oral antivirals
2020-001528-32Phase 3Terminated
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of lopinavir + ritonavir, darunavir + cobicistat, hydroxychloroquine and favipiravir in coronavirus disease 2019 (COVID-19) and Viral lower respiratory tract infection (VLRTI) (4 arms), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoint: Primary virologic outcome at day 7. Started Jun 2020; status: terminated.
02
Drugs
lopinavir + ritonavirdarunavir + cobicistathydroxychloroquinefavipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)Viral lower respiratory tract infection (VLRTI)
Beyond the preview
Go deeper on 2020-001528-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001528-32.